Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Phase 3 trials (the TRIUMPH programme, registered on ClinicalTrials.gov) are currently underway, evaluating retatrutide across broader populations including those with cardiovascular disease, type 2 diabetes, and obesity-related complications
Encapsulation Liposomes are one of the most suitable carriers with minimal toxicity and high accuracy of drug delivery in vitro
doi:10.1002/cber.190203503211
Scope of the Report GLP-1 Diabetes Treatment Drugs Market by Segments Drug Type: Liraglutide Dulaglutide Exenatide Others Application: Online Pharmacy Hospital Clinic Region: North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Nordic BENELUX Rest of Europe East Asia China Japan South Korea South Asia & Pacific India ASEAN Australia & New Zealand Rest of South Asia & Pacific Latin America Brazil Chile Rest of Latin America Middle East & Africa Kingdom of Saudi Arabia Other GCC Countries Turkiye South Africa Other African Union Rest of Middle East & Africa Frequently Asked Questions How big is the GLP-1 diabetes treatment drugs market in 2025
Mild taste with little to no aftertaste
US$ 27.95
US$ 22.56
US$ 23.77
US$ 20.93
US$ 20.25
US$ 24.56
US$ 24.76
